How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Sell
49
BLFS Quote, Financials, Valuation and Earnings
Last price:
$22.59
Seasonality move
:
-0.62%
Day range:
$22.88 - $25.22
52-week range:
$19.10 - $29.62
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
10.97x
P/B ratio:
3.12x
Volume:
180K
Avg. volume:
317.3K
1-year change:
-19.48%
Market cap:
$1.1B
Revenue:
$82.3M
EPS (TTM):
-$0.07
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BLFS
BioLife Solutions, Inc.
|
$24M | $0.01 | 5.9% | -98.07% | $32.44 |
|
DXCM
DexCom, Inc.
|
$1.3B | $0.65 | 13.59% | 79.17% | $85.19 |
|
IVF
INVO Fertility, Inc.
|
$1.9M | -- | -8.8% | -- | -- |
|
NMTC
NeuroOne Medical Technologies Corp.
|
$2.7M | -- | -57.64% | -57.14% | $2.30 |
|
NTRB
Nutriband, Inc.
|
$675K | -$0.17 | 4.52% | -54.85% | $15.00 |
|
SINT
SINTX Technologies, Inc.
|
$300K | -$0.55 | -44.65% | -56.43% | $12.25 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BLFS
BioLife Solutions, Inc.
|
$22.93 | $32.44 | $1.1B | -- | $0.00 | 0% | 10.97x |
|
DXCM
DexCom, Inc.
|
$73.36 | $85.19 | $28.6B | 40.83x | $0.00 | 0% | 6.62x |
|
IVF
INVO Fertility, Inc.
|
$1.62 | -- | $24.5M | -- | $0.00 | 0% | 0.03x |
|
NMTC
NeuroOne Medical Technologies Corp.
|
$0.91 | $2.30 | $45.7M | -- | $0.00 | 0% | 3.01x |
|
NTRB
Nutriband, Inc.
|
$4.70 | $15.00 | $57.1M | -- | $0.00 | 0% | 23.45x |
|
SINT
SINTX Technologies, Inc.
|
$3.32 | $12.25 | $12.8M | -- | $0.00 | 0% | 5.63x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BLFS
BioLife Solutions, Inc.
|
5.52% | 0.467 | 1.69% | 3.31x |
|
DXCM
DexCom, Inc.
|
48.58% | 1.837 | 9.81% | 1.33x |
|
IVF
INVO Fertility, Inc.
|
41.99% | 0.410 | 10.12% | 0.07x |
|
NMTC
NeuroOne Medical Technologies Corp.
|
3.64% | 3.209 | 0.6% | 3.40x |
|
NTRB
Nutriband, Inc.
|
3.31% | 3.036 | 0.32% | 7.07x |
|
SINT
SINTX Technologies, Inc.
|
45.47% | 0.781 | 22.94% | 1.47x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BLFS
BioLife Solutions, Inc.
|
$17.2M | -$89K | -4.73% | -5.11% | -0.32% | $2.8M |
|
DXCM
DexCom, Inc.
|
$747.4M | $242.5M | 14.67% | 30.94% | 20.05% | $579.4M |
|
IVF
INVO Fertility, Inc.
|
$492.6K | -$1.6M | -188.23% | -471.28% | -93.08% | -$1.8M |
|
NMTC
NeuroOne Medical Technologies Corp.
|
$1.5M | -$1.4M | -83.42% | -89.54% | -50.02% | -$1.5M |
|
NTRB
Nutriband, Inc.
|
$63K | -$3.9M | -159.71% | -164.64% | -1121.15% | -$1.8M |
|
SINT
SINTX Technologies, Inc.
|
-$66K | -$3.4M | -115.95% | -208.36% | -1612.98% | -$2.6M |
BioLife Solutions, Inc. vs. Competitors
-
Which has Higher Returns BLFS or DXCM?
DexCom, Inc. has a net margin of 2.21% compared to BioLife Solutions, Inc.'s net margin of 23.47%. BioLife Solutions, Inc.'s return on equity of -5.11% beat DexCom, Inc.'s return on equity of 30.94%.
Company Gross Margin Earnings Per Share Invested Capital BLFSBioLife Solutions, Inc.61.36% $0.01 $374.4M DXCMDexCom, Inc.61.8% $0.70 $5.3B -
What do Analysts Say About BLFS or DXCM?
BioLife Solutions, Inc. has a consensus price target of $32.44, signalling upside risk potential of 29.88%. On the other hand DexCom, Inc. has an analysts' consensus of $85.19 which suggests that it could grow by 16.13%. Given that BioLife Solutions, Inc. has higher upside potential than DexCom, Inc., analysts believe BioLife Solutions, Inc. is more attractive than DexCom, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BLFSBioLife Solutions, Inc.9 0 0 DXCMDexCom, Inc.20 3 0 -
Is BLFS or DXCM More Risky?
BioLife Solutions, Inc. has a beta of 1.929, which suggesting that the stock is 92.869% more volatile than S&P 500. In comparison DexCom, Inc. has a beta of 1.480, suggesting its more volatile than the S&P 500 by 48.047%.
-
Which is a Better Dividend Stock BLFS or DXCM?
BioLife Solutions, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DexCom, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioLife Solutions, Inc. pays -- of its earnings as a dividend. DexCom, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BLFS or DXCM?
BioLife Solutions, Inc. quarterly revenues are $28.1M, which are smaller than DexCom, Inc. quarterly revenues of $1.2B. BioLife Solutions, Inc.'s net income of $621K is lower than DexCom, Inc.'s net income of $283.8M. Notably, BioLife Solutions, Inc.'s price-to-earnings ratio is -- while DexCom, Inc.'s PE ratio is 40.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioLife Solutions, Inc. is 10.97x versus 6.62x for DexCom, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BLFSBioLife Solutions, Inc.10.97x -- $28.1M $621K DXCMDexCom, Inc.6.62x 40.83x $1.2B $283.8M
-
Which has Higher Returns BLFS or IVF?
INVO Fertility, Inc. has a net margin of 2.21% compared to BioLife Solutions, Inc.'s net margin of -150.51%. BioLife Solutions, Inc.'s return on equity of -5.11% beat INVO Fertility, Inc.'s return on equity of -471.28%.
Company Gross Margin Earnings Per Share Invested Capital BLFSBioLife Solutions, Inc.61.36% $0.01 $374.4M IVFINVO Fertility, Inc.28.04% -$6.14 $10.1M -
What do Analysts Say About BLFS or IVF?
BioLife Solutions, Inc. has a consensus price target of $32.44, signalling upside risk potential of 29.88%. On the other hand INVO Fertility, Inc. has an analysts' consensus of -- which suggests that it could grow by 8788.89%. Given that INVO Fertility, Inc. has higher upside potential than BioLife Solutions, Inc., analysts believe INVO Fertility, Inc. is more attractive than BioLife Solutions, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BLFSBioLife Solutions, Inc.9 0 0 IVFINVO Fertility, Inc.0 0 0 -
Is BLFS or IVF More Risky?
BioLife Solutions, Inc. has a beta of 1.929, which suggesting that the stock is 92.869% more volatile than S&P 500. In comparison INVO Fertility, Inc. has a beta of 2.606, suggesting its more volatile than the S&P 500 by 160.551%.
-
Which is a Better Dividend Stock BLFS or IVF?
BioLife Solutions, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. INVO Fertility, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioLife Solutions, Inc. pays -- of its earnings as a dividend. INVO Fertility, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BLFS or IVF?
BioLife Solutions, Inc. quarterly revenues are $28.1M, which are larger than INVO Fertility, Inc. quarterly revenues of $1.8M. BioLife Solutions, Inc.'s net income of $621K is higher than INVO Fertility, Inc.'s net income of -$2.6M. Notably, BioLife Solutions, Inc.'s price-to-earnings ratio is -- while INVO Fertility, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioLife Solutions, Inc. is 10.97x versus 0.03x for INVO Fertility, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BLFSBioLife Solutions, Inc.10.97x -- $28.1M $621K IVFINVO Fertility, Inc.0.03x -- $1.8M -$2.6M
-
Which has Higher Returns BLFS or NMTC?
NeuroOne Medical Technologies Corp. has a net margin of 2.21% compared to BioLife Solutions, Inc.'s net margin of -59.08%. BioLife Solutions, Inc.'s return on equity of -5.11% beat NeuroOne Medical Technologies Corp.'s return on equity of -89.54%.
Company Gross Margin Earnings Per Share Invested Capital BLFSBioLife Solutions, Inc.61.36% $0.01 $374.4M NMTCNeuroOne Medical Technologies Corp.55.77% -$0.03 $7.3M -
What do Analysts Say About BLFS or NMTC?
BioLife Solutions, Inc. has a consensus price target of $32.44, signalling upside risk potential of 29.88%. On the other hand NeuroOne Medical Technologies Corp. has an analysts' consensus of $2.30 which suggests that it could grow by 153.64%. Given that NeuroOne Medical Technologies Corp. has higher upside potential than BioLife Solutions, Inc., analysts believe NeuroOne Medical Technologies Corp. is more attractive than BioLife Solutions, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BLFSBioLife Solutions, Inc.9 0 0 NMTCNeuroOne Medical Technologies Corp.1 0 0 -
Is BLFS or NMTC More Risky?
BioLife Solutions, Inc. has a beta of 1.929, which suggesting that the stock is 92.869% more volatile than S&P 500. In comparison NeuroOne Medical Technologies Corp. has a beta of 0.575, suggesting its less volatile than the S&P 500 by 42.534%.
-
Which is a Better Dividend Stock BLFS or NMTC?
BioLife Solutions, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NeuroOne Medical Technologies Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioLife Solutions, Inc. pays -- of its earnings as a dividend. NeuroOne Medical Technologies Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BLFS or NMTC?
BioLife Solutions, Inc. quarterly revenues are $28.1M, which are larger than NeuroOne Medical Technologies Corp. quarterly revenues of $2.7M. BioLife Solutions, Inc.'s net income of $621K is higher than NeuroOne Medical Technologies Corp.'s net income of -$1.6M. Notably, BioLife Solutions, Inc.'s price-to-earnings ratio is -- while NeuroOne Medical Technologies Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioLife Solutions, Inc. is 10.97x versus 3.01x for NeuroOne Medical Technologies Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BLFSBioLife Solutions, Inc.10.97x -- $28.1M $621K NMTCNeuroOne Medical Technologies Corp.3.01x -- $2.7M -$1.6M
-
Which has Higher Returns BLFS or NTRB?
Nutriband, Inc. has a net margin of 2.21% compared to BioLife Solutions, Inc.'s net margin of -1118.87%. BioLife Solutions, Inc.'s return on equity of -5.11% beat Nutriband, Inc.'s return on equity of -164.64%.
Company Gross Margin Earnings Per Share Invested Capital BLFSBioLife Solutions, Inc.61.36% $0.01 $374.4M NTRBNutriband, Inc.18.2% -$0.32 $7.8M -
What do Analysts Say About BLFS or NTRB?
BioLife Solutions, Inc. has a consensus price target of $32.44, signalling upside risk potential of 29.88%. On the other hand Nutriband, Inc. has an analysts' consensus of $15.00 which suggests that it could grow by 219.15%. Given that Nutriband, Inc. has higher upside potential than BioLife Solutions, Inc., analysts believe Nutriband, Inc. is more attractive than BioLife Solutions, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BLFSBioLife Solutions, Inc.9 0 0 NTRBNutriband, Inc.1 0 0 -
Is BLFS or NTRB More Risky?
BioLife Solutions, Inc. has a beta of 1.929, which suggesting that the stock is 92.869% more volatile than S&P 500. In comparison Nutriband, Inc. has a beta of 1.840, suggesting its more volatile than the S&P 500 by 84.015%.
-
Which is a Better Dividend Stock BLFS or NTRB?
BioLife Solutions, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nutriband, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioLife Solutions, Inc. pays -- of its earnings as a dividend. Nutriband, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BLFS or NTRB?
BioLife Solutions, Inc. quarterly revenues are $28.1M, which are larger than Nutriband, Inc. quarterly revenues of $346.1K. BioLife Solutions, Inc.'s net income of $621K is higher than Nutriband, Inc.'s net income of -$3.9M. Notably, BioLife Solutions, Inc.'s price-to-earnings ratio is -- while Nutriband, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioLife Solutions, Inc. is 10.97x versus 23.45x for Nutriband, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BLFSBioLife Solutions, Inc.10.97x -- $28.1M $621K NTRBNutriband, Inc.23.45x -- $346.1K -$3.9M
-
Which has Higher Returns BLFS or SINT?
SINTX Technologies, Inc. has a net margin of 2.21% compared to BioLife Solutions, Inc.'s net margin of -1701.44%. BioLife Solutions, Inc.'s return on equity of -5.11% beat SINTX Technologies, Inc.'s return on equity of -208.36%.
Company Gross Margin Earnings Per Share Invested Capital BLFSBioLife Solutions, Inc.61.36% $0.01 $374.4M SINTSINTX Technologies, Inc.-31.73% -$3.46 $7.5M -
What do Analysts Say About BLFS or SINT?
BioLife Solutions, Inc. has a consensus price target of $32.44, signalling upside risk potential of 29.88%. On the other hand SINTX Technologies, Inc. has an analysts' consensus of $12.25 which suggests that it could grow by 268.98%. Given that SINTX Technologies, Inc. has higher upside potential than BioLife Solutions, Inc., analysts believe SINTX Technologies, Inc. is more attractive than BioLife Solutions, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BLFSBioLife Solutions, Inc.9 0 0 SINTSINTX Technologies, Inc.2 0 0 -
Is BLFS or SINT More Risky?
BioLife Solutions, Inc. has a beta of 1.929, which suggesting that the stock is 92.869% more volatile than S&P 500. In comparison SINTX Technologies, Inc. has a beta of 0.649, suggesting its less volatile than the S&P 500 by 35.053%.
-
Which is a Better Dividend Stock BLFS or SINT?
BioLife Solutions, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SINTX Technologies, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioLife Solutions, Inc. pays -- of its earnings as a dividend. SINTX Technologies, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BLFS or SINT?
BioLife Solutions, Inc. quarterly revenues are $28.1M, which are larger than SINTX Technologies, Inc. quarterly revenues of $208K. BioLife Solutions, Inc.'s net income of $621K is higher than SINTX Technologies, Inc.'s net income of -$3.5M. Notably, BioLife Solutions, Inc.'s price-to-earnings ratio is -- while SINTX Technologies, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioLife Solutions, Inc. is 10.97x versus 5.63x for SINTX Technologies, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BLFSBioLife Solutions, Inc.10.97x -- $28.1M $621K SINTSINTX Technologies, Inc.5.63x -- $208K -$3.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.7T
P/E Ratio: 65x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Sell
48
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Buy
72
BNAI alert for Jan 29
Brand Engagement Network, Inc. [BNAI] is down 16.89% over the past day.
Buy
82
STX alert for Jan 29
Seagate Technology Holdings Plc [STX] is up 0.83% over the past day.
Buy
84
GDXU alert for Jan 29
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 12.19% over the past day.
